Trump signs executive order to expedite psychedelic therapy research
Here's what it means for you.
This executive order could reshape the future of mental health treatments and drug policy in the U.S.
What happened
Trump signed an executive order to expedite psychedelic research and access.
The Context
- The order could facilitate studies on the medical use of psychedelics like psilocybin and LSD.
- There are concerns about the implications for federal drug policy and the pace of research.
- Psychedelic stocks have seen significant increases following the announcement.
Takeaway
The executive order may lead to significant advancements in psychedelic therapy research and its acceptance in mainstream medicine.
This article was generated by AI from 4 verified sources and reviewed by A47 editorial systems.
Global business headlines with AI angles.
"General business outlet that frequently covers AI."
— A47 Editor
New Psychedelics Push by Donald Trump Raises Questions About Federal Drug Policy Delays
Donald Trump has initiated a new order aimed at accelerating research into psychedelics, which has sparked discussions regarding the slow pace of federal drug policy reforms. This move seeks to address the growing interest in psychedelic substances f...
Science and technology stories including AI.
"Longstanding science magazine with thoughtful AI coverage."
— A47 Editor
Trump’s order on psychedelics could have far-reaching science consequences
President Trump has signed an executive order aimed at facilitating research into the medical applications of psychedelic substances, including psilocybin, LSD, and ibogaine. This initiative is expected to enhance the scientific understanding of thes...
Scientific research, technology, environment, and society.
"Scientific American is one of the oldest and most authoritative science magazines, known for deep dives into science, technology, and society."
— A47 Editor
Trump’s order on psychedelics could have far-reaching science consequences
President Trump has signed an executive order aimed at facilitating research into the medical applications of psychedelic substances, including psilocybin, LSD, and ibogaine. This initiative is expected to enhance the scientific understanding of thes...
Global markets, investing, and macroeconomics from a premier financial newsroom.
"Bloomberg is respected for in-depth financial reporting and data-driven analysis."
— A47 Editor
Psychedelic Stocks Soar as Trump Signs Order to Ease Access
Shares of companies involved in psychedelic therapies have surged following President Donald Trump's executive order aimed at expediting research and access to these treatments. This move has sparked significant interest in the market, reflecting a g...
Conservative-leaning coverage of current events.
"Fox News is a highly influential conservative news outlet known for right-leaning political commentary and coverage."
— A47 Editor
Trump-backed plan could fast-track psychedelic therapies — here’s what to know
President Donald Trump signed an executive order on April 18, 2026, directing the FDA to expedite the review process for psychedelic drugs, including ibogaine and psilocybin, which are being considered for their potential therapeutic benefits in trea...